08-07-2018 05:26 PM CET - Health & Medicine

Newborn Screening Market Outlook 2018 (Low Density Polyethylene, Ethylene Vinyl Acetate, Polypropylene )| With Key Players Analysis On: DiaDx, Roche, Myriad Genetics, Qiagen, Exosome Sciences, Inc., Inivata Limited

Press release from: Data Bridge Market Research
Newborn Screening Market
Newborn Screening Market
Global Newborn Screening Market study with depth analysis, describing about the Service & Industry demand and explain market outlook and status to 2025. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are DiaDx, Roche, Myriad Genetics, Qiagen, Exosome Sciences, Inc., Inivata Limited

This report Describe the Global Newborn Screening Market size, industry status, scope and Demand forecast, competition landscape and growth opportunity. This research report categorizes the Global Newborn Screening Market by companies, region, type and end-use industry.

Get Free Sample of Research Report: databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Global Newborn Screening Market is estimated to reach USD 2,258.12 million by 2025 from USD 1,008.64 million in 2017, at a CAGR of 10.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Newborn Screening Market Major Players:

Some of the prominent players operating in this market are-
• PerkinElmer Inc.,
• Trivitron Healthcare,
• Interacoustics A/S ,
• Bio-Rad Laboratories, Inc.,
• Natus Medical Incorporated,
• Masimo,
• Medtronic,
• Intelligent Hearing Systems,
• Interacoustics A/S,
• Otodynamics Ltd,
• Vivosonic Inc.,
• ZenTech S.A.,
• AB Sciex, Welch Allyn,
• Baebies, Inc.

Market Scope: Newborn Screening Market

• The global newborn screening market is segmented on the basis of test types into dried blood spot (DBS) test, critical congenital heart diseases (CCHD) test and hearing screen test. In 2018, dried blood spot segment is projected to dominate the market with a share of around 44.0%.

• The global newborn screening market is segmented on the basis of product type into instruments and reagents & assay kits. In 2018, the instruments segment is estimated to dominate market with a share of around 68.0%. The instruments are further sub-segmented into newborn disorder screening, newborn hearing screening, and pulse oximeter.

• The global newborn screening market is segmented on the basis of technologies into tandem mass spectrometry, hearing screen, pulse oximetry screening, immunoassays and enzymatic assays, electrophoresis and DNA-based assays. In 2018, tandem mass spectrometry segment is likely to dominate the market and it is expected to grow at the highest CAGR in the forecast period.

• The global newborn screening market is segmented on the basis of disease type into phenylketonuria, cystic fibrosis, sickle cell disease, newborn hearing loss, critical congenital heart diseases, maple syrup urine disease and others. In 2018, critical congenital heart diseases segment will dominate the market and is projected to reach 1,492.98 million by 2025.

• The global newborn screening market is divided on the basis of end user into hospitals, pediatric clinics, and clinics. In 2018, hospitals segment is expected to dominate market with a share of around 70% and is estimated to grow at the highest CAGR of 10.9%.

• Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa.

Speak to Research Analyst for Further Query: databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...


Newborn screening is the testing used in the diagnoses of harmful and fatal disorders in newborns, which can adversely affect their long term health. Early detection and diagnosis of disorders will reduce the death along with the diseases and associated disabilities.

Currently, this screening tests around thirty metabolic and genetic diseases. Some of them are phenylketonuria (PKU), congenital hypothyroidism (CH), galactosemia (GAL), and sickle cell disease. The screening program offers appropriate diagnosis, treatment, and ongoing evaluation.

• According to American Academy of Paediatrics (AAP), in 2018, an article published that stated that each year 4.1 million new-borns are screened for congenital disorders in the U.S. Out of which four thousands infants are detected with disorder and it is assessed that another 1,000 infants were undetected with conditions.

• According to National Institute of Child Health and Human Development (NICHD), about 4 million infants are born each year in the U.S. and it is reported that 99.9% or higher number of infants were screened.

• According to World Health Organization (WHO), neonatal mortality has been decreased. This is because people have started choosing newborn screening. This is because it detects the disorder effectively as compared to other practices.

Read More About This Report@ databridgemarketresearch.com/reports/global-newborn-scree...

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research
Tel: +1-888-387-281
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1167326 • Views: 525
More releasesMore releases

You can edit or delete your press release here: